SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549

FORM 10-QSB

QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarter ended December 31, 2005

Commission File Number 0-10683

HYDROMER, INC.

(Exact name of registrant as specified in its charter)

N a w	(=::::::::::::::::::::::::::::::::::::
Ne w Jersey	22-2303576
(State of incorporation)	(I.R.S. Employer
	Identification No.)
35 Industrial P Branchburg, N Jersey	•
(Address of principal executoffices)	(Zip Code) utive
Registrant's	

Securities registered pursuant to Section 12 (b) of the Act: None

Securities registered pursuant to Section 12 (g) of the Act:

Common Stock Without Par Value (Title of class)

Check whether the issuer (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities
Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to
file such report(s), and (2) has been subject to such filing requirements for the past 90 days

.YesxNo"

Indicate the number of shares outstanding or each of the issuer's classes of Common Stock as of the close of the period covered by this report.

Class Outstanding at December 31, 2005

Common 4,644,164

- 1 -

HYDROMER, INC.

INDEX TO FORM 10-QSB December 31, 2005

Part I - Financial I	Page No.			
Consolidated Final	ncial Statements			
Balance Sheets - D	2			
Statements of Inco ended December 31, 200	3			
		J		
Statements of Casl December 31, 200	4			
Notes to Financial	5			
Management's Dis Condition	cussion and Analysis of the Financial			
and Results of Ope	erations	6		
Part II - Other Info	8			
	EXHIBIT INDEX			
Exhibit No. 33.1	Description of Exhibit SEC Section 302 Certification - CEO certification	10)	
33.2				
<u>99.1</u>	Certification of Manfred F. Dyck, Chie Executive Officer, pursuant to 18 U.S.C. Section 1350			
99.2	12	2		
	Financial Officer, pursuant to 18 U.S.C. Section 1350	12	2	

- 2 -

HYDROMER, INC. and CONSOLIDATED SUBSIDIARY CONSOLIDATED BALANCE SHEETS

Assets	December 31, 2005 UNAUDITED		June 30, 2005 AUDITED	
Current Assets:				
Cash and cash equivalents	\$	451,883.	\$	1,376,656
Short-term investments		397,968.		-
Trade receivables less allowance for doubtful				
accounts of \$32,753 as of		987,297.		1,220,258
December 31, 2005 and June 30, 2005				
Inventory		1,111,337.		1,094,927
Prepaid expenses		100,670.		126,762
Deferred tax asset		34,589.		91,989
Other		47,492.		14,841
Total Current Assets		3,131,236.		3,925,433
Property and equipment, net		3,252,116.		3,276,258
Deferred tax asset, non current				-
		250,000		
Intangible assets, net		805,247.		780,140
Goodwill, net		238,172.		238,172
Total Assets	\$	7,676,771.	\$	8,220,003
Liabilities and Stockholders' Equity				
Current Liabilities:				
Accounts payable	\$	464,964.	\$	466,993
Short-term borrowings	Ψ	284,933.	Ψ	206,663
Accrued expenses		194,696.		280,944
Bonus payable		-		77,267
Current portion of deferred revenue		188,151.		161,317
Current portion of mortgage payable		195,805.		178,029
Income Taxes payable		2,328.		-
Total Current Liabilities		1,330,877.		1,371,213
Deferred tax liability		243,864.		243,864
Long-term portion of deferred revenue		139,071.		176,979
Long-term portion of mortgage payable		2,196,342.		2,295,292
Total Liabilities		3,910,154.		4,087,348
Total Bluemites		0,510,101		1,007,510
Stockholders' Equity				
Preferred stock - no par value, authorized				
1,000,000 shares, no shares		-		-
issued and outstanding				
Common stock - no par value, authorized				
15,000,000 shares;				

as of December 31, 2005, 4,655,081 shares issued and 4,644,164 shares outstanding; as of June 30, 2004, 4,608,904 shares issued and 4,597,987 shares outstanding	3,639,315.	3,631,615
Contributed capital	577,750.	577,750
Accumulated deficit	(444,308)	(70,570).
Treasury stock, 10,917 common shares at cost	(6,140)	(6,140).
Total Stockholders' Equity	3,766,617.	4,132,655
Total Liabilities and Stockholders' Equity	\$ 7,676,771.	\$ 8,220,003

HYDROMER, INC. and CONSOLIDATED SUBSIDIARY CONSOLIDATED STATEMENTS OF INCOME

		Three Months Ended		Six Months Ended		
		December 31,		nber 31,		
	2005	2004	2005	2004		
	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED		
Revenues						
Sale Sale of	\$ 1,161,379					
products	245,481	303,683	490,764	585,312		
ServService						
revenues	45.6.050	(75.401	1 025 442	1.260.050		
RoyRoyalties	476,272	675,421	1,037,443	1,268,959		
and Contract						
Revenues Total						
Revenues	1,883,132	2,181,696	3,744,336	4,128,026		
Revenues	1,003,132	2,161,090	3,744,330	4,120,020		
Expenses						
-						
Cost of Sales	803,384	757,406	1,620,732	1,456,163		
Operating		,	,, -	, ,		
Expenses	1,242,355	1,302,102	2,624,089	2,579,886		
Other		25 790	<i>45</i> 70 <i>1</i>	17.560		
Expenses	32,221	25,780	65,784	47,560		
(Benefit)						
Provision for						
Income	(66,241)	39,618	(192,531)	11,012		
Taxes						
m						
Total	2 011 710	2 124 006	4 110 074	4.004.601		
Expenses	2,011,719	2,124,906	4,118,074	4,094,621		
Net (Loss)	(128,587)	\$ 56,790\$	(373,738)	\$ 33,405		
Income	(120,50 <i>1</i>)	y 30,790 t	(3/3,/30)	5 33,403		
(Loss)	(0.03)	\$ 0.01\$	(0.08)	\$ 0.01		
Earnings Per	(0.00)	Ψ 0.01	(0,00)	Ψ 0.01		
Common						
Share	\$					
Weighted						
Average	4,643,217	4,613,150	4,634,362	4,605,569		
Number of						

Common Shares Outstanding

The effects of the common stock equivalents on diluted earnings per share are not included as they have no impact.

- 4 -

HYDROMER, INC. and CONSOLIDATED SUBSIDIARY CONSOLIDATED STATEMENTS OF CASH FLOWS

	Six Months Ended December 31,		
	2005	2004	
	UNAUDITED	UNAUDITED	
Cash Flows From Operating Activities:			
Net (Loss) Income	\$ (373,738)	\$ 33,405	
Adjustments to reconcile net (loss) income			
to net cash provided by (used for) operating			
activities			
Depreciation and amortization	113,085	97,452	
Deferred income taxes	(192,600)	(6,581)	
Changes in Assets and Liabilities			
Trade receivables	232,961	(137,467)	
Inventory	(16,410)	(84,936)	
Prepaid expenses	26,092	38,019	
Patents and Trademark	(25,107)	(91,424)	
Other assets	(37,986)	(43)	
Accounts payable and accrued liabilities	(176,618)	109,216	
Income taxes payable	2,328	(48,207)	
• •	,		
Net Cash Used for Operating Activities	(447,993)	(90,566)	
ı	, , ,		
Cash Flows From Investing Activities:			
Cash purchases of property and equipment	(88,943)	(291,584)	
Cash purchases of short-term investments	(392,633)	-	
1	, , ,		
Net Cash Used for Investing Activities	(481,576)	(291,584)	
S	, , ,	, , ,	
Cash Flows From Financing Activities:			
Net borrowings against Line of Credit	78,270	521,629	
Repayment of long-term borrowings	(81,174)	(44,731)	
Proceeds from the issuance of common	7,700	16,000	
stock	,	,	
Net Cash Provided by Financing	4,796	492,898	
Activities	,	· ,	
Net (Decrease) Increase in Cash and	(924,773)	110,748	
Cash Equivalents:	, , ,	,	
Cash and Cash Equivalents at Beginning of	1,376,656	142,476	
Period	, , ,	, -	
Cash and Cash Equivalents at End of Period	451,883	\$ 253,224	

- 5 -

HYDROMER, INC. and CONSOLIDATED SUBSIDIARY

Notes to Consolidated Financial Statements

In the opinion of management, the accompanying unaudited financial statements include all adjustments (consisting of only normal adjustments) necessary for a fair presentation of the results for the interim periods. Certain reclassifications have been made to the previous year's results to present comparable financial statements.

Segment Reporting:

The Company operates two primary business segments. The Company evaluates the segments by revenues, total expenses and earnings before taxes. Corporate Overhead is excluded from the business segments as to not distort the contribution of each segment.

The results for the six months ended December 31, by segment are:

	Polymer	Medical	Corporate	
	Research	Products	Overhead	Total
2005				
Revenues	\$	\$		\$
	2,203,554	1,540,782		3,744,336
Expenses	(1,812,623)	(1,771,260)	\$	(4,310,605)
			(726,722)	
Pre-tax Loss	\$	\$	\$	\$
	390,931	(230,478)	(726,722)	(566,269)
2004				
Revenues	\$	\$		\$
	2,613,612	1,514,414		4,128,026
Expenses	(1,674,740)	(1,682,874)	\$	(4,083,609)
			(725,995)	
Pre-tax Income (Loss)	\$	\$	\$	\$ 44,417
	938,872	(168,460)	(725,995)	

The prior period segment information has been restated to conform to the current year presentation.

Geographic revenues were as follows for the six months ended December 31,

2005 2004 Domestic 84% 82% Foreign 16% 18%

- 6 -

MANAGEMENT'S DISCUSSION AND ANALYSIS OF THE FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Results of Operations

The Company's revenues for the quarter ended December 31, 2005 were \$1,883,132 as compared to \$2,181,696 for the same period last year or a 13.7% decrease. Revenues for the six months ended December 31, 2005 were \$3,744,336, down 9.3% from \$4,128,026 the corresponding period a year ago. Revenues are comprised of the sale of Products and Services and Royalty and Contract payments.

Product sales and services were \$1,406,860 for the quarter ended December 31, 2005 as compared to \$1,506,275 for the same period last year, a decrease of \$99,415 or 6.6% lower. For the six months ended December 31, 2005, product sales and services were \$2,706,893 as compared to \$2,859,067 the prior year, a 5.3% decrease or \$152,174. The absence of paid R&D services this year compared with the prior year (\$233,737) was the primary variance. One of the R&D customers last year converted over to contract coating services.

Royalty and Contract revenues includes royalties received and the payments from license, option and other agreements which calls for periodic recurring payments for other than product and services. Included in Royalty and Contract revenues are revenues from support and supply agreements. For the quarter, Royalty and Contract revenues were \$476,272, down 29.5% from \$675,421 the same period a year ago. For the six months ended December 31, 2005, Royalty and Contract revenues were \$1,037,443, down 18.2% from \$1,268,959 the same period a year ago. The expiration of the Company's '267 patent in May 2005 eliminated approximately \$525,000 in quarterly royalty revenues from four licensees. The Company was successful in reaching new agreements with three of the four former licensees during the quarter ended September 30, 2005. A tentative agreement with the fourth former licensee was reached during the quarter ended December 31, 2005. The new agreements, primarily supply and availability agreements, provided approximately \$492,000 and \$437,000 for the quarters ended September 30, and December 31, 2005, respectively.

As of December 31, 2005, our open sales order book for delivery this fiscal year was approximately \$1,520,000. Although some of these orders are subject to cancellation, the Company is of the opinion that no substantial cancellations will occur. Our open order book excludes though, future orders that would come up during the normal course of business for immediate delivery also during the fiscal year.

Total Expenses for the quarter ended December 31, 2005 were \$2,011,719 as compared with \$2,124,906 the year before, a decrease of 5.3%. For the six months ended December 31, 2005, total Expenses were \$4,118,074 as compared with \$4,094,621 the same period the year before, essentially flat with an increase of 0.6%.

The Company's Cost of Goods Sold was \$803,384 for the quarter ended December 31, 2005 as compared with \$757,406 the year prior, an increase of 6.1%. On a year-to-date basis, cost of goods sold was \$1,620,732 this year as compared with \$1,456,163 the corresponding period a year ago, an increase of 11.3%. The change in the mix of higher cost margin products sold this year in addition to higher direct labor costs (including fringe benefits) resulted in a higher cost of goods sold.

Operating expenses were \$1,242,355 for the quarter ended December 31, 2005 as compared with \$1,302,102 the year before, lower by \$59,747 or 4.6%. For the six month periods, operating expenses were \$2,624,089 this year as compared with \$2,579,886 the previous year, higher by \$44,203 or 1.7%. The Company expended an additional \$165,000 in litigation costs this fiscal year-to-date in its continued infringement claim against a former licensee and other parties, as compared with \$80,000 the corresponding six months a year ago. The total direct legal burden to the

Company on this action to-date is \$418,000, and should begin to tail-off as settlement agreements to resolve this matter are being finalized and is expected to be announced in the next few weeks. Irrespective of the settlement, our legal actions to protect our intellectual property ceased the infringement by the defending parties allowing the Company to realize additional sales during the past few years.

- 7 -

INDEX

Interest expense, included in Other Expenses, for the six months ended December 31, 2005 and December 31, 2004 were \$80,849 and \$50,934, respectively, higher as a result of the mortgage refinance on June 30, 2005. The refinance provided to the Company an additional \$1,091,643 in funds which the Company is using for working capital requirements and investments in short-term instruments.

A net loss of \$128,587 (\$0.03 per share) is reported for the quarter ended December 31, 2005 as compared to net income of \$56,790 (\$0.01 per share) the year before. For the six months ended December 31, 2005, a net loss of \$373,738 (\$0.08 per share) is reported as compared to Net Income of \$33,405 (\$0.01 per share) the year before.

Although the Company's sales are not cyclical, our revenues have been historically higher in the second half of our fiscal year. The lack of paid R&D services combined with higher costs and expenses, part of which being investment back into the Company (primarily from an increase in R&D staffing), increased current operating expenses for expected returns in the future. Our self-funded developmental projects, including those in cardiovascular and neurological applications, are typically long-term initiatives where the costs are incurred before any revenues are returned.

Financial Condition

Working capital decreased \$753,861 during the six months ended December 31, 2005.

Net operating activities used \$447,993 for the six month period ended December 31, 2005.

The net loss as adjusted for non-cash expenses, used \$453,253 in net cash, including an income tax benefit of \$192,600 recorded as a deferred tax asset, mostly non-current. The net cash provided from working capital accounts was \$5,260: primarily from to the decrease in accounts receivables by \$232,961 as offset by a decrease in accounts payable and accrued liabilities and deferred income of \$176,618 and the increase in patent and trademarks and other assets by \$63,093.

Investing activities used \$481,576 and financing activities provided \$4,796 during the six months ended December 31, 2005.

During the quarter, the Company purchased \$392,633 in 6-month U.S. Treasury Bills, recorded as short-term investments, and expended \$88,943 on capital expenditures. The Company also repaid down long-term borrowings by \$81,174 while utilizing an additional \$78,270 from its revolving line of credit during the period.

Management believes that its current working capital and available line of credit, along with expected income and expense streams, are sufficient to maintain its current level of operations.

Disclosure Controls and Procedures

The evaluation of the Company's Internal Controls Environment concluded that it was effective for the safeguarding of assets and in ensuring that management is presented material information regarding the organization. The evaluation also determined that there are areas that could be improved upon; however, the controls and procedures in place were appropriate for the type and size of the Company.

INDEX

The Company has again reviewed its Internal Controls Environment during the prior 90 days, and it has been determined that there have been no significant changes in internal controls or in other factors that could significantly affect the financial statements.

PART II - Other Information

The Company operates entirely from its sole location at 35 Industrial Parkway in Branchburg, New Jersey, an owned facility secured by mortgages through banks.

The existing facility will be adequate for the Company's operations for the foreseeable future.

Item 6. Exhibits and Reports on form 8-K:

- a) Exhibits none
- b) Reports on form 8-K There were four Form 8-K's filed during the quarter ending

 December 31, 2005. Two announced supply agreements, one on a new FDA

 510(k) clearance and one announcing the earnings for the quarter ending September 30, 2005.

- 9 -

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on his behalf by the undersigned thereunto duly authorized.

HYDROMER, INC.

/s/ Robert Y. Lee Robert Y. Lee Chief Financial Officer

DATE: February 6, 2006

- 10 -